These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9004585)

  • 1. Interleukin-2 therapy for renal cell cancer: indications, effects, and nursing implications.
    Letizia M; Conway AM
    Crit Care Nurse; 1996 Oct; 16(5):20-6, 30-2, 34-5. PubMed ID: 9004585
    [No Abstract]   [Full Text] [Related]  

  • 2. Case management of the hospitalized patient receiving interleukin-2.
    Sharp E
    Semin Oncol Nurs; 1993 Aug; 9(3 Suppl 1):14-9. PubMed ID: 8210789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in therapy of renal cell cancer.
    Rugarli C
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S19-20. PubMed ID: 2697574
    [No Abstract]   [Full Text] [Related]  

  • 4. Concepts in advanced renal carcinoma.
    Esper P
    Semin Oncol Nurs; 2012 Aug; 28(3):170-9. PubMed ID: 22846485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal cell carcinoma and interleukin-2: what are the endpoints?
    Figlin RA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S68-9. PubMed ID: 9457397
    [No Abstract]   [Full Text] [Related]  

  • 6. A teaching tool for patients receiving continuous i.v. infusion recombinant interleukin-2 therapy.
    Sharp E; DePriest C; Potts LA; Willeford R
    Oncol Nurs Forum; 1994 Jun; 21(5):911-2. PubMed ID: 7937252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive cellular therapy of renal carcinoma.
    West WH
    Prog Clin Biol Res; 1989; 303():689-96. PubMed ID: 2789392
    [No Abstract]   [Full Text] [Related]  

  • 8. Interleukin-2.
    Med Lett Drugs Ther; 1987 Sep; 29(749):88-9. PubMed ID: 3306301
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of interleukin-2 alone in disseminated renal cell carcinoma: an update.
    Javadpour N; Lalehzarian M
    Prog Clin Biol Res; 1989; 303():671-9. PubMed ID: 2789391
    [No Abstract]   [Full Text] [Related]  

  • 10. Are you prepared for interleukin-2?
    Muehlbauer PM; White RL
    RN; 1998 Feb; 61(2):34-8; quiz 39. PubMed ID: 9485881
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapeutic approaches for renal cancer.
    Pizza G; de Vinci C; Viza D
    Folia Biol (Praha); 2002; 48(5):167-81. PubMed ID: 12448765
    [No Abstract]   [Full Text] [Related]  

  • 12. Managing side effects associated with IL-2 therapy.
    Hynes M; Bournes L; Brich A; Cupernall G; Hanzelin J; Ramming K; Pitler LR
    Oncol Nurs Forum; 1990; 17(6):963-4. PubMed ID: 2263525
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal-cell carcinoma.
    Atkins MB; Dutcher JP
    N Engl J Med; 1997 Mar; 336(11):809; author reply 810-1. PubMed ID: 9064517
    [No Abstract]   [Full Text] [Related]  

  • 14. Recombinant interleukin-2 and the quest for FDA approval.
    Tami JA
    Clin Pharm; 1991 Feb; 10(2):141-2. PubMed ID: 2009733
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
    J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better survival with interleukin-2-based regimens? Possibly only in highly selected patients.
    Négrier S
    J Clin Oncol; 2004 Apr; 22(7):1174-6. PubMed ID: 14981101
    [No Abstract]   [Full Text] [Related]  

  • 18. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.